Pharmacotherapy of Major Depression with Psychotic Features: What is the Evidence?
Department of Psychiatry
Depressive Disorder, Major; Affective Disorders, Psychotic
Major depression with psychotic features (MD-Psy) is a significant public health problem. In American studies, between 15% (community sample, ECA) and 25% (inpatient sample) of mixed-age patients who meet criteria for major depressive disorder present with psychotic features. Similarly, in a large European epidemiological study, 19% of noninstitutionalized people ages 19 to 100 with major depression had psychotic features. Among geriatric patients who require hospitalization for the treatment of their depression, the prevalence of MD-Psy may reach 45%. Compared with patients with nonpsychotic depression, patients with MD-Psy exhibit greater impairment following resolution of the depressive episode, greater risk of relapse and recurrence, increased number of suicide attempts, prolonged hospitalizations, increased comorbidity, and increased financial dependence.
Andreescu C, Mulsant BH, Rothschild AJ, Flint AJ, Meyers BS: Pharmacotherapy of Major Depression with Psychotic Features – What is the Evidence? Psych Annals, 2006; 36:31-38.
Carmen Andreescu C, Mulsant BH, Rothschild AJ, Flint AJ, Meyers BS, Whyte EM. (2006). Pharmacotherapy of Major Depression with Psychotic Features: What is the Evidence?. Psychiatry Publications and Presentations. Retrieved from https://escholarship.umassmed.edu/psych_pp/99